Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0461929603
Tue, 01.11.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
ProcCluster® from portfolio company inflamed pharma granted US patent
01.11.2022 / 07:00 CET/CEST
Xlife Sciences AG (SIX: XLS) announced today that its portfolio company inflamed pharma has been granted a patent by the United States Patent and Trademark Office (USPTO) for the manu [ … ]
Tue, 01.11.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
ProcCluster® from portfolio company inflamed pharma granted US patent
01.11.2022 / 07:00 CET/CEST
Xlife Sciences AG (SIX: XLS) announced today that its portfolio company inflamed pharma has been granted a patent by the United States Patent and Trademark Office (USPTO) for the manu [ … ]
Wed, 28.09.2022
Xlife Sciences AG
Xlife Sciences (SIX: XLS) today published its results for the first half of 2022 ending 30 June 2022. Oliver R. Baumann, CEO Xlife Sciences, comments: “In implementing our strategy of bridging preclinical research & development to healthcare markets, we have achieved relevant steps despite a challenging market environment and can look back on s [ … ]
Wed, 28.09.2022
Xlife Sciences AG
Xlife Sciences (SIX: XLS) today published its results for the first half of 2022 ending 30 June 2022. Oliver R. Baumann, CEO Xlife Sciences, comments: “In implementing our strategy of bridging preclinical research & development to healthcare markets, we have achieved relevant steps despite a challenging market environment and can look back on s [ … ]
Mon, 26.09.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Project company Laxxon Medical achieves major milestone
26.09.2022 / 07:00 CET/CEST
Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms
Strengthening the Position of Laxxon Medical’s Intellectual Property in the Pharmaceutical Marke [ … ]
Mon, 26.09.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Project company Laxxon Medical achieves major milestone
26.09.2022 / 07:00 CET/CEST
Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms
Strengthening the Position of Laxxon Medical’s Intellectual Property in the Pharmaceutical Marke [ … ]
Wed, 21.09.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Xlife Sciences strengthens sustainability activities with ESG strategy
21.09.2022 / 07:00 CET/CEST
One of the objectives of Xlife Sciences (SIX: XLS) is to significantly strengthen and further develop its existing sustainability activities on a strategic and operational level. For th [ … ]
Wed, 21.09.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Xlife Sciences strengthens sustainability activities with ESG strategy
21.09.2022 / 07:00 CET/CEST
One of the objectives of Xlife Sciences (SIX: XLS) is to significantly strengthen and further develop its existing sustainability activities on a strategic and operational level. For th [ … ]
Thu, 15.09.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Baader Bank initiates research coverage on Xlife Sciences
15.09.2022 / 07:00 CET/CEST
Baader Bank, one of the leading European partners for investment and banking services, has initiated its research coverage on Xlife Sciences (SIX: XLS). The initial analyst report published today st [ … ]
Thu, 15.09.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Baader Bank initiates research coverage on Xlife Sciences
15.09.2022 / 07:00 CET/CEST
Baader Bank, one of the leading European partners for investment and banking services, has initiated its research coverage on Xlife Sciences (SIX: XLS). The initial analyst report published today st [ … ]